Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. - Wikidata - awgldk - TriplyDB

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

http://www.wikidata.org/entity/Q31037298

about

Oral deferiprone for iron chelation in people with thalassaemia Oral deferiprone for iron chelation in people with thalassaemia Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases More pieces to the iron chelation puzzle.Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells Nanoparticle and iron chelators as a potential novel Alzheimer therapy.Iron chelation therapy in myelodysplastic syndromes.Advances in iron chelation: an update.Functional characterization of the ferroxidase, permease high-affinity iron transport complex from Candida albicans Red ginseng abrogates oxidative stress via mitochondria protection mediated by LKB1-AMPK pathway Plasmodium drug targets outside the genetic control of the parasite.A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload.Clinical assay of four thiol amino acid redox couples by LC-MS/MS: utility in thalassemia Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload.Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.Iron storage disease: facts, fiction and progress.Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine Cardiac magnetic resonance in myocardial disease Iron depletion limits intracellular bacterial growth in macrophages New therapeutic targets in atrophic age-related macular degeneration.Hereditary iron and copper deposition: diagnostics, pathogenesis and therapeutics.Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis.Cost analysis of iron-related complications in a single institute.Iron is essential for oligodendrocyte genesis following intraspinal macrophage activation.Iron homeostasis and eye disease.Management of transfusional iron overload in Latin America: current outlook and expert panel recommendations.Deferasirox pharmacokinetics in patients with adequate versus inadequate response.Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion.Evaluation of myocardial iron overload using magnetic resonance imaging.Malaria and iron: history and review.Beta-thalassemia.Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.An update on disordered iron metabolism and iron overload.Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.Iron overload and allogeneic hematopoietic stem-cell transplantation.The role of iron in tumour cell proliferation.

P2860

Q24200309-E17B6A25-E5B7-4A6E-A612-073E282E7029 Q24244045-7F695CDB-2701-4273-8218-82806A1B4F58 Q28388335-46BBD5F6-7C87-4131-B97E-BFD7958C1786 Q33349435-F59D991B-379A-4182-A753-7E46A762B81B Q33397094-B25AA090-6BD1-44A6-B180-EC485FE368C7 Q33534491-D386CE0C-924A-4BA5-9B64-A67136D6DA89 Q33720596-A92DC868-652A-4D6E-B330-F04F22DEF812 Q34002840-E1E0743E-4DE0-450C-BDC5-F7AA525C01A7 Q34174307-F5DDB90D-11F6-4446-87A4-8A6A4C78FECC Q34190117-FADC4BCD-F665-44E8-99A0-E18BF1E2D1DF Q34626622-F0EC6A63-FE57-4DA4-BA2A-C5A2278DA412 Q34678568-41B72381-8121-4890-BC35-F360075EBA8E Q34750514-2F0B9200-D41E-4A55-8BD5-D3C1CC202863 Q34798959-42A94F15-E7A3-4B80-A49B-95D3041681A6 Q35107121-5DDF81EE-CAEA-4B77-8C47-6861A0B2CF0F Q35485724-242F5FC1-9475-44E0-AB3A-4160781D6968 Q35876935-E922AB42-D459-461C-A356-D344EBFF11F1 Q35911202-C7611767-A324-4B4F-A691-3A042127003F Q36073089-BF2172D9-AC34-4D52-93A4-C5713EB5812A Q36498403-B8D14609-5BEA-46DF-96C4-8C0F26B843C4 Q36498834-36652AE9-616A-49CC-8394-04FC88008ABE Q36787471-C5B453C5-DF10-4435-BF7A-1DE14B81C9E5 Q36804427-5D8439BC-14AE-4ECC-9057-AF8D08657AED Q36823912-7B46FC6E-9B68-41FD-8342-11332F5A8913 Q37114840-6F568426-EE5A-43D9-BA59-CAAC3BBDE254 Q37205325-A149B0DF-719B-48BC-B5E9-2FE82FBB99BD Q37243956-EAC99A07-D05F-4D18-B0E8-94400CE5BE16 Q37342236-9B6B7EE5-BE14-4A87-9A8E-095425E1A207 Q37372868-C967D567-C9BB-4272-8EB3-4DB8F4545687 Q37414682-D5112881-8E32-4A66-8B93-F04B205D5FC2 Q37428097-FA0DD351-53DF-4605-A1E2-B721BAF21D14 Q37528626-2EA46AFE-8F1D-46E0-8B43-108A7D7CA429 Q37573422-1DE1CB79-0DCA-40C8-9C28-43746C7F1B60 Q37599856-3DD68A8D-A515-4693-9945-B8C5B1701402 Q37680651-040432AB-3765-411D-93B5-4CFC610B512A Q37734245-C171CB17-FB11-4271-9EEE-8BA9CB4A672C Q37791615-EB803761-696B-4A1D-960D-2E494DBB1731 Q37809009-6EFDF1F9-CAF0-46AE-94AA-6F12FC29668A Q37842351-0E16D2A4-5D3F-492A-A465-9DA51F10E77D Q37842957-2F967CB2-FC99-47D4-8703-54C1C43D5118

P2860

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

http://www.wikidata.org/entity/Q31037298

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Oral chelators deferasirox and ...... ajor: new data, new questions.

@ast

Oral chelators deferasirox and ...... ajor: new data, new questions.

@en

type

label

Oral chelators deferasirox and ...... ajor: new data, new questions.

@ast

Oral chelators deferasirox and ...... ajor: new data, new questions.

@en

prefLabel

Oral chelators deferasirox and ...... ajor: new data, new questions.

@ast

Oral chelators deferasirox and ...... ajor: new data, new questions.

@en

P1433

Q31037298-3A464DEE-FB70-4252-804B-A09CDC583035

P1476

Q31037298-6ADEF59D-E8D8-4387-89E5-08D75D48AF69

P2093

Q31037298-BCFC60BD-FE94-40CC-95C6-23973BA66514

P2860

Q31037298-01B4E083-58BF-4AF0-AA4A-B40D44599ED7

Q31037298-099A7968-C102-4B39-B2E2-89A867CB9E84

Q31037298-0CDB6896-DAB9-4144-BADA-969C03BB28DC

Q31037298-0E795829-A8B4-4CF0-B71C-D1F3C3DB496C

Q31037298-10DE2EDD-DD95-447F-A564-6F5293473577

Q31037298-2843C190-1C17-418C-8B0B-0F9881100062

Q31037298-2EBD0D00-B5F9-4E8B-8FD7-E6C445F813D9

Q31037298-3DC42BC0-01AC-4D92-BD6C-B90EDC9AD7A7

Q31037298-4D6DEEBF-474B-4698-98B9-ACE265533F09

Q31037298-54CA5BB5-5665-4B3F-8240-72FF598CECCC

P304

Q31037298-9A63A23D-BA90-4AE1-A508-B97AC00632E2

P31

Q31037298-2b27d407-c0e1-429b-899d-c86b2839b005

Q31037298-CBDEB86F-67ED-4EFF-807E-01C9FBAA043D

P356

Q31037298-B714597E-52CB-48A5-A429-57554300C2B9

P407

Q31037298-505E376E-3FCF-4C50-8009-35976896C98E

P433

Q31037298-FB94D25B-1303-4115-99E1-7526D2778C3E

P478

Q31037298-6AC7DC4A-5DDD-4DE1-B546-38C261AFA23A

P577

Q31037298-D779DD13-7A3A-4E38-81CB-4DFE34C7878D

P5875

Q31037298-0F8E96BB-3E1D-4AEB-BA83-CC03F9782832

P698

Q31037298-F3156D78-25EE-4EA1-AF1D-55B5DAD3F606

P932

Q31037298-48324F8A-98FA-4D30-AF0F-0D6FEE846C01

P356

BLOOD-2006-02-002394

P1433

P1476

Oral chelators deferasirox and ...... ajor: new data, new questions.

@en

P2093

Ellis J Neufeld

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major

ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.

Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy.

Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease.

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.

Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.

Iron-chelating therapy and the treatment of thalassemia.

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

Role of deferiprone in chelation therapy for transfusional iron overload.

P304

3436-3441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-02-002394

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7152385

http://www.w3.org/2001/XMLSchema#string

P698

16627763

http://www.w3.org/2001/XMLSchema#string

P932

1895765

http://www.w3.org/2001/XMLSchema#string